2-benzylisoindoline-5-carboxylic acid | 164648-51-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-benzylisoindoline-5-carboxylic acid
• 英文别名: 2-benzyl-1,3-dihydroisoindole-5-carboxylic acid
• CAS: 164648-51-5
• 化学式: C₁₆H₁₅NO₂
• 分子量: 253.301
• InChiKey: QNUOZOFEABCOGU-UHFFFAOYSA-N

物化性质

• 沸点：
  403.0±45.0 °C(Predicted)
• 密度：
  1.263±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-benzylisoindoline-5-carboxylic acid 在 palladium on activated charcoal 、 氢气 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0~30.0 ℃ 、101.33 kPa 条件下， 反应 112.5h， 生成
  参考文献：
  名称：

  Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α-amino amide as the zinc-binding unit

  摘要：

  A series of potent inhibitors of histone deacetylase-8 (HDAC8) is described that contains an a-amino amide zincbinding unit and a substituted isoindolinyl capping group. The presence of a 2,4-dichlorophenyl unit located in the acetate-release cavity was shown to confer a gain of approx. 4.3 kJ mol(-1) in binding energy compared to a phenyl group, and the isoindoline linker has approx. 5.8 kJ mol(-1) greater binding energy than the corresponding tetrahydroisoquinoline ring system. In a series of 5-substituted isoindolin-2-yl inhibitors, a 5-acetylamino derivative was found to be more potent than the 5-unsubstituted lead HDAC8 inhibitor (increase in binding energy of 2.0 kJ mol(-1), ascribed to additional binding interactions within the N-epsilon-acetyl-L-lysine binding tunnel in HDAC8, including hydrogen bonding to Asp101. Tolerance of a 5-substituent (capping group) on the isoindoline ring has been demonstrated, and which in some cases confers improved enzyme inhibition, the HDAC8 substrate-binding region providing a platform for additional interactions.

  DOI：

  10.1016/j.bmcl.2019.126926
• 作为产物：
  描述：

  2-苄基-5-溴-1H-异吲哚-1,3(2H)-二酮 在 sodium tetrahydroborate 、 正丁基锂 、 三氟化硼乙醚 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 20.0h， 生成 2-benzylisoindoline-5-carboxylic acid
  参考文献：
  名称：

  Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α-amino amide as the zinc-binding unit

  摘要：

  A series of potent inhibitors of histone deacetylase-8 (HDAC8) is described that contains an a-amino amide zincbinding unit and a substituted isoindolinyl capping group. The presence of a 2,4-dichlorophenyl unit located in the acetate-release cavity was shown to confer a gain of approx. 4.3 kJ mol(-1) in binding energy compared to a phenyl group, and the isoindoline linker has approx. 5.8 kJ mol(-1) greater binding energy than the corresponding tetrahydroisoquinoline ring system. In a series of 5-substituted isoindolin-2-yl inhibitors, a 5-acetylamino derivative was found to be more potent than the 5-unsubstituted lead HDAC8 inhibitor (increase in binding energy of 2.0 kJ mol(-1), ascribed to additional binding interactions within the N-epsilon-acetyl-L-lysine binding tunnel in HDAC8, including hydrogen bonding to Asp101. Tolerance of a 5-substituent (capping group) on the isoindoline ring has been demonstrated, and which in some cases confers improved enzyme inhibition, the HDAC8 substrate-binding region providing a platform for additional interactions.

  DOI：

  10.1016/j.bmcl.2019.126926

文献信息

• [DE] AMINOSÄUREDERIVATE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL UND VERFAHREN ZU IHRER HERSTELLUNG<br/>[EN] AMINOACID DERIVATES, MEDICAMENTS CONTAINING THESE COMPOUNDS AND PROCESS FOR PREPARING THE SAME<br/>[FR] DERIVES D'AMINO-ACIDES, MEDICAMENTS CONTENANT CES COMPOSES ET PROCEDE PERMETTANT DE LES PREPARER
  申请人：DR. KARL THOMAE GMBH

  公开号：WO1994017035A1

  公开（公告）日：1994-08-04

  (DE) Die Erfindung betrifft neue Aminosäurederivate der allgemeinen Formel: T-Z-NR1-(R2CR3)-CO-Y-(CH2)n-R, in der R, R1 bis R3, T, Z, Y und n wie im Anspruch 1 definiert sind, deren Diastereomere, deren Enantiomere und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle NPY-antagonistische Wirkstoffe darstellen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung.(EN) New aminoacid derivates have the general formula: T-Z-NR1-(R2CR3)-CO-Y-(CH2)n-R, in which R, R1 to R3, T, Z, Y and n are defined as in the first claim. They represent valuable NPY-antagonistic active substances. Also disclosed are their diastereomers, their enantiomers and their salts, in particular their physiologically tolerable salts with inorganic or organic acids or bases, as well as medicaments containing these compounds, their use and a process for preparing the same.(FR) L'invention concerne de nouveaux dérivés d'amino-acides de la formule: T-Z-NR1-(R2CR3)-CO-Y-(CH2)n-R, dans laquelle R, R1 à R3, T, Z, Y et n ont la notation mentionnée dans la revendication 1. L'invention concerne également leurs diastéréomères, leurs énantiomères et leurs sels, notamment leurs sels physiologiquement tolérables avec des acides ou des bases inorganiques ou organiques. Ces dérivés d'amino-acides constituent des substances antagonistes de NPY intéressantes. L'invention concerne par ailleurs des médicaments qui contiennent ces composés, leur utilisation et leur procédé de préparation.

  这项发明涉及新的氨基酸衍生物，其通用化学式为：T-Z-NR1-(R2CR3)-CO-Y-(CH2)n-R，其中R、R1至R3、T、Z、Y和n的定义见附图1。这种衍生物以及它们在化学结构上可能形成的异构体、它们的单体和它们的共轭体，尤其是它们的物理上相容性强的盐，其中包括在无机或有机酸或碱的情况下与不产生副作用的盐，这些物质是重要的抗NPY活性剂。此外，还涉及包含这些化合物的药物以及它们的使用和制备方法。
• [EN] HETEROCYCLIC COMPOUND ACTING AS ASK INHIBITOR AND USE THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE AGISSANT EN TANT QU'INHIBITEUR D'ASK ET UTILISATION DE CELUI-CI<br/>[ZH] 作为ASK抑制剂的杂环化合物及其应用
  申请人：NANJING SANHOME PHARMACEUTICAL CO LTD

  公开号：WO2019015559A1

  公开（公告）日：2019-01-24

  本发明属于医药化学领域，涉及一类作为ASK抑制剂的杂环化合物及其应用，具体地，本发明提供式A所示的化合物或其异构体、药学上可接受的盐、溶剂化物、结晶或前药，它们的制备方法以及含有这些化合物的药物组合物和这些化合物或组合物用于治疗和/或预防细胞凋亡信号调节激酶1相关的疾病的用途。本发明的化合物具有优异的细胞凋亡信号调节激酶1抑制活性，非常有希望成为细胞凋亡信号调节激酶1相关疾病的治疗剂。
• AMINOSÄUREDERIVATE, DIESE VERBINDUNGEN ENTHALTENDE ARZNEIMITTEL UND VERFAHREN ZU IHRER HERSTELLUNG
  申请人：Boehringer Ingelheim Pharma KG

  公开号：EP0680469B1

  公开（公告）日：2000-04-26
• US5616620A
  申请人：——

  公开号：US5616620A

  公开（公告）日：1997-04-01
• Potent non-hydroxamate inhibitors of histone deacetylase-8: Role and scope of an isoindolin-2-yl linker with an α-amino amide as the zinc-binding unit
  作者：Simon O.R. Greenwood、A.W. Edith Chan、D. Flemming Hansen、Charles M. Marson

  DOI：10.1016/j.bmcl.2019.126926

  日期：2020.3

  A series of potent inhibitors of histone deacetylase-8 (HDAC8) is described that contains an a-amino amide zincbinding unit and a substituted isoindolinyl capping group. The presence of a 2,4-dichlorophenyl unit located in the acetate-release cavity was shown to confer a gain of approx. 4.3 kJ mol(-1) in binding energy compared to a phenyl group, and the isoindoline linker has approx. 5.8 kJ mol(-1) greater binding energy than the corresponding tetrahydroisoquinoline ring system. In a series of 5-substituted isoindolin-2-yl inhibitors, a 5-acetylamino derivative was found to be more potent than the 5-unsubstituted lead HDAC8 inhibitor (increase in binding energy of 2.0 kJ mol(-1), ascribed to additional binding interactions within the N-epsilon-acetyl-L-lysine binding tunnel in HDAC8, including hydrogen bonding to Asp101. Tolerance of a 5-substituent (capping group) on the isoindoline ring has been demonstrated, and which in some cases confers improved enzyme inhibition, the HDAC8 substrate-binding region providing a platform for additional interactions.